CN109453151B - Pharmaceutical composition for eyes, preparation method and application thereof - Google Patents
Pharmaceutical composition for eyes, preparation method and application thereof Download PDFInfo
- Publication number
- CN109453151B CN109453151B CN201811551020.2A CN201811551020A CN109453151B CN 109453151 B CN109453151 B CN 109453151B CN 201811551020 A CN201811551020 A CN 201811551020A CN 109453151 B CN109453151 B CN 109453151B
- Authority
- CN
- China
- Prior art keywords
- composition
- use according
- taurine
- vitamin
- regulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Abstract
The invention relates to the field of ophthalmic preparations, in particular to an ophthalmic pharmaceutical composition, a preparation method and application thereof. Every 1000ml of the composition comprises 0.05-0.15g of naphazoline hydrochloride, 3.2-5.8g of taurine, 0.1-0.3g of pH regulator, 0.05-0.15g of osmotic pressure regulator, 0.01-0.05g of metal ion complexing agent, 0.2-0.5g of vitamin B12 and 0.1-0.3g of chlorphenamine. The combination of taurine, naphazoline hydrochloride, vitamin B12 and chlorphenamine is synergistic, the treatment effect of the composition on conjunctivitis is improved, the treatment effect on congestion, edema and the like caused by inflammation is good, the side effect of the composition can be obviously reduced, the stimulation of the composition on eyes is reduced, and the experience of the patient on medication is improved.
Description
Technical Field
The invention relates to the field of ophthalmic preparations, in particular to an ophthalmic pharmaceutical composition, a preparation method and application thereof.
Background
The naproxen vitamin eye drops are non-prescription medicines of ophthalmic medicines and can be used for relieving symptoms such as eye fatigue, conjunctival congestion, eye itching and the like. The naphazoline is an adrenomimetic receptor agonist and has the function of contracting capillary vessels of eyes, so the naphazoline has a good effect on conjunctival congestion, and the chlorpheniramine and the vitamin B12 have the functions of relieving allergic symptoms of the eyes and maintaining the nerve function of the eyes respectively, but after the naphazoline eye drops are used for a long time, the blood pressure of the contracted blood vessels rebounds to cause pain of the eyes, so that the medication compliance of patients is poor.
Disclosure of Invention
The present invention aims to provide a pharmaceutical composition for ophthalmic use which has an excellent therapeutic effect on conjunctival congestion, eye fatigue and the like and does not cause ocular pressure rebound after a prolonged period of use.
The invention also aims to provide a preparation method of the ophthalmic medicinal composition, which has simple process and controllable quality and can quickly prepare the ophthalmic medicinal composition.
Another object of the present invention is to provide an ophthalmic pharmaceutical composition with an expanded application range and improved practicability.
The technical problem to be solved by the invention is realized by adopting the following technical scheme:
the invention provides an ophthalmic pharmaceutical composition, wherein each 1000ml of the composition comprises 0.05-0.15g of naphazoline hydrochloride, 3.2-5.8g of taurine, 0.1-0.3gpH regulator, 0.05-0.15g of osmotic pressure regulator, 0.01-0.05g of metal ion complexing agent, 0.2-0.5g of vitamin B12 and 0.1-0.3g of chlorpheniramine.
The invention provides a preparation method of a pharmaceutical composition for eyes, which comprises the following steps: naphazoline hydrochloride, taurine, a pH adjuster, an osmotic pressure adjuster, a metal ion complexing agent, vitamin B12, and chlorpheniramine are mixed to form a composition.
The invention provides an application of an ophthalmic pharmaceutical composition in preparing a medicine for improving intraocular pressure rebound phenomenon and an application in preparing a medicine for treating conjunctivitis.
The ophthalmic pharmaceutical composition, the preparation method and the application thereof have the beneficial effects that: the ophthalmic medicine composition combines taurine, naphazoline hydrochloride, vitamin B12 and chlorphenamine, has synergistic effect, improves the treatment effect of the ophthalmic medicine composition on conjunctivitis, has good treatment effect on congestion, edema and the like caused by inflammation, can obviously reduce the side effect of the ophthalmic medicine composition, reduces the stimulation of the ophthalmic medicine composition on eyes, and improves the experience of patients on medication. Meanwhile, the antibacterial agent has a certain antibacterial effect, can kill germs, and further improves the treatment effect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
In the description of the present invention, it should be noted that the terms "first", "second", and the like are used only for distinguishing the description, and are not intended to indicate or imply relative importance.
The pharmaceutical composition for eye use, the preparation method thereof and the use thereof according to the embodiments of the present invention are specifically described below.
The ophthalmic pharmaceutical composition provided by the embodiment of the invention comprises 0.05-0.15g of naphazoline hydrochloride, 3.2-5.8g of taurine, 0.1-0.3gpH regulator, 0.05-0.15g of osmotic pressure regulator, 0.01-0.05g of metal ion complexing agent, 0.2-0.5g of vitamin B12 and 0.1-0.3g of chlorpheniramine per 1000ml of the composition. Or 0.08-0.1g of naphazoline hydrochloride, 4-5g of taurine, 0.15-0.2g of pH regulator, 0.1-0.12g of osmotic pressure regulator, 0.03-0.04g of metal ion complexing agent, 0.3-0.4g of vitamin B12 and 0.15-0.25g of chlorpheniramine are contained in every 1000ml of the composition.
In the prior art, the naproxen vitamin eye drops can relieve symptoms such as eye fatigue and conjunctival congestion, but the naproxen vitamin eye drops are stopped taking medicine after being used for a long time, so that blood pressure rebound easily occurs, and conjunctiva of a patient is congested again or the patient feels eye pain.
Meanwhile, the stability of the composition can be ensured by adding the osmotic pressure regulator, the pH regulator and the metal ion complexing agent, the composition is prevented from going bad, and meanwhile, the composition is more beneficial to the absorption of each effective component in the composition by a human body, so that the treatment effect of the composition is improved.
Furthermore, the synergistic effect of the active ingredients in the composition can be further ensured by controlling the proportion of each material, the quality and the treatment effect of the composition can be ensured, and if the proportion of each material in the composition is changed, the synergistic effect is easily reduced, so that the treatment effect of the composition is reduced.
Further, the metal ion complexing agent is an aminopolycarboxylic acid metal complexing agent, preferably disodium edetate. The complexing agent can combine metal ions, prevent the composition from deteriorating and reduce the irritation of the composition to eyes.
Further, the pH adjuster is an inorganic acid, preferably a monobasic acid, more preferably boric acid. The substances are used as the pH regulator, so that each active ingredient in the composition can be absorbed more favorably, and the irritation of the composition to eyes is reduced.
Further, the osmotic pressure regulator is an organic substance, preferably an alcohol substance, more preferably a polyhydric alcohol, and most preferably glycerin. The glycerin, namely the glycerol, is used as the osmotic pressure regulator, so that the irritation of the composition to eyeballs can be reduced, the absorption effect of the medicine can be improved, and the treatment effect of the medicine can be further improved.
Furthermore, the composition also comprises 0.01-0.03g of preservative per 1000ml, and the preservative is further added into the composition, so that the shelf life of the composition can be further prolonged, and the production cost can be reduced.
Further, the preservative is a cationic surfactant, preferably benzalkonium bromide. The preservative substance can prolong the shelf life of the composition, and can improve the performance of the composition in killing bacteria, thereby improving the efficacy of the composition.
Further, the balance of the 1000mL ophthalmic pharmaceutical composition is water for injection.
The invention also provides a preparation method of the ophthalmic medicine composition, which comprises the following steps:
firstly, the dosage of each substance is calculated according to the formula, and then the vitamin B12 powder is mixed with water for injection to obtain a vitamin B12 solution.
The taurine and a proper amount of injection water are mixed and dissolved, so that the materials can be uniformly mixed, the taurine can be fully mixed with the naphazoline hydrochloride, the vitamin B12 and the chlorphenamine, and the synergistic effect is ensured.
Adding a proper amount of injection water into the reactor, heating to 60-80 ℃, heating the injection water, improving the solubility of each substance, and facilitating the uniform mixing of each substance. Then mixing with osmotic pressure regulator, metal ion complexing agent and pH regulator, and mixing with naphazoline hydrochloride, chlorphenamine, vitamin B12 solution and taurine.
If the formula contains a preservative, the preservative is added after the taurine is added. Then the liquid medicine is cooled after being continuously stirred for 25 to 40 minutes at the temperature of between 60 and 80 ℃, and the temperature is kept to be continuously stirred, which is more beneficial to uniformly mixing all the raw materials in the composition. After cooling, filtering and fixing the volume to ensure that each raw material meets the specification.
The invention also provides application of the ophthalmic medicinal composition in preparing a medicament for improving rebound phenomenon and preparing a medicament for treating conjunctivitis.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
This example provides an ophthalmic pharmaceutical composition (1000mL) comprising 0.05g naphazoline hydrochloride, 3.2g taurine, 0.1g boric acid, 0.05g glycerol, 0.01g edetate disodium, 0.2g vitamin B12, and 0.1g chlorpheniramine.
The present invention also provides a method for preparing an ophthalmic pharmaceutical composition:
dissolving vitamin B12 powder in water for injection to obtain vitamin B12 solution;
dissolving taurine in the injection water to obtain a taurine solution;
adding a proper amount of injection water into a reactor, heating to 70 ℃, mixing with boric acid, glycerol and disodium edetate, mixing with naphazoline hydrochloride and chlorphenamine maleate, mixing with a vitamin B12 solution and a taurine solution, keeping the temperature at 70 ℃, stirring for 30 minutes, cooling, and adding the injection water to fix the volume.
Examples 2 to 6
Examples 2 to 6 provide the same raw materials as those of the ophthalmic pharmaceutical composition provided in example 1, except for the specific amounts; examples 2 to 6 provide ophthalmic pharmaceutical compositions prepared by substantially the same method as that of example 1, except that the operating conditions are different.
Example 2
An ophthalmic pharmaceutical composition (1000mL) comprises 0.15g naphazoline hydrochloride, 5.8g taurine, 0.3g boric acid, 0.15g glycerol, 0.05g edetate disodium, 0.5g vitamin B12 and 0.3g chlorpheniramine. The heating temperature was 60 ℃ and the stirring was continued for 40 minutes.
Example 3
An ophthalmic pharmaceutical composition (1000mL) comprises 0.1g naphazoline hydrochloride, 4g taurine, 0.15g boric acid, 0.12g glycerol, 0.03g edetate disodium, 0.4g vitamin B12 and 0.15g chlorpheniramine. The heating temperature was 80 ℃ and the stirring was continued for 25 minutes.
Example 4
An ophthalmic pharmaceutical composition (1000mL) comprises 0.08g naphazoline hydrochloride, 5g taurine, 0.2g boric acid, 0.1g glycerol, 0.04g edetate disodium, 0.3g vitamin B12 and 0.25g chlorpheniramine. The heating temperature was 65 ℃ and the stirring time was 35 minutes.
Example 5
An ophthalmic pharmaceutical composition (1000mL) comprises 0.09g naphazoline hydrochloride, 4.5g taurine, 0.17g boric acid, 0.11g glycerol, 0.035g edetate disodium, 0.35g vitamin B12, 0.03g benzalkonium bromide and 0.2g chlorpheniramine. The heating temperature was 75 ℃ and the stirring was continued for 38 minutes.
Example 6
An ophthalmic pharmaceutical composition (1000mL) comprises 0.07g naphazoline hydrochloride, 3.5g taurine, 0.25g boric acid, 0.08g glycerol, 0.02g edetate disodium, 0.25g vitamin B12, 0.01g benzalkonium bromide and 0.15g chlorpheniramine. The heating temperature was 66 ℃ and the stirring duration was 32 minutes.
Comparative example 1: a composition was prepared according to the preparation method provided in example 1, except that the taurine content was 3.25g, naphazoline hydrochloride was not contained, and the contents of the remaining components were unchanged.
Comparative example 2: a composition was prepared according to the preparation method provided in example 1, except that 3.25g of naphazoline hydrochloride, taurine was not contained, and the contents of the remaining components were unchanged.
Animal experiments:
wistar rats of 60 animals, each half of which is male and female, are selected, the body weight of the rats is 80-120 g, the rats are randomly divided into 6 groups, 10 rats in each group are selected, one group is a control group, and the remaining 5 groups are experimental groups. Each group was modeled for conjunctivitis: the mouse head was fixed, the eyelid was pulled down, 200. mu.l of 10% croton oil inflammatory agent was dropped per eye, and the solution was washed away with physiological saline after being kept in the conjunctival sac for 45 seconds. The liquid medicine is respectively dripped for 1h, 3h, 6h and 12h after the successful inflammation, the injection water is dripped for the control group, and the compositions of the example 1, the example 5, the comparative example 1, the comparative example 2 and the comparative example 3 are dripped for the experimental group in sequence, and the dripping amount is 2-3 drops. According to ocular inflammatory manifestations: lacrimation, viscous secretions, conjunctival congestion, edema, and corneal edema. The degree of ocular conjunctivitis was scored according to the ocular irritation response scoring standard of the ministry of health, "research on new drug guidelines on traditional Chinese medicine", and the results are shown in table 1.
TABLE 1 test results
As can be seen from Table 1, the irritability of the naproxen containing taurine to eyes of mice with inflammation of conjunctiva of eyes is obviously lower than that of the naproxen containing no taurine, and after the naproxen containing taurine is taken for 12 hours, the irritability to eyes of the eye drops formed by each prescription is not obviously different.
Taking 30 rats (without cornea turbidity, conjunctiva congestion, edema and secretion) with no damage in eye detection, dividing the rats into 6 groups randomly, wherein each group comprises 5 rats, one group is a control group, adding injection water dropwise, and the rest 5 groups are experimental groups, and sequentially adding the compositions of example 1, example 5, comparative example 1, comparative example 2 and comparative example 3 dropwise; the dripping amount is 50ul (1-2 drops), and the dripping is continuously carried out for 15 days, 3 times per day.
Whether the cornea, iris and conjunctiva have irritation before the first administration and after 5 minutes and 30 minutes after the administration is directly observed with naked eyes or observed with a magnifier, and the irritation is scored, the scoring standard is shown in table 2(cn102670494.b), then the total score is calculated according to the scoring standard, the irritation is judged according to the total score, the judging standard is shown in table 3, the average score (total score/5) is calculated, and the evaluation result is shown in table 4.
TABLE 2 evaluation criteria
TABLE 3 evaluation of irritation
| Score value | 0-3 | 4-8 | 9-12 | 13-16 |
| Evaluation of | Has no irritation | Mild stimulation | Moderate stimulation | Stimulation of intensity |
TABLE 4 test results
As can be seen from table 4, the ophthalmic solution containing taurine has significantly lower eye irritation to the mouse with no damage to the eyes than the ophthalmic solution containing taurine, and the ophthalmic solution containing taurine still has slight irritation to the eyes after 30 min.
50 rats (with no corneal opacity, conjunctival congestion, edema and secretion) with no damage in eye detection were randomly divided into 5 groups, and eye drops composed of different components were administered in an amount of 50ul (1-2 drops) continuously for 15 days, 3 times per day. Subsequently, according to the American Heart Association (AHA) "guidelines for measuring blood pressure in humans and animals", the effect of the rat using eye drops of different composition on its blood pressure was measured using a rat tail sensor which is an indirect measurement method, and the results are shown in Table 5.
TABLE 5 Effect of different drugs on blood pressure results
According to table 5, the influence of the naproxen vitamin eye drops containing taurine on the intraocular pressure of the mouse without damage to eyes is obviously lower than that of the naproxen vitamin eye drops containing no taurine, and no obvious intraocular pressure rebound phenomenon occurs after stopping the drug administration, so that the increase of the intraocular pressure is avoided, and the irritation is enhanced.
The bacteriostatic efficacy verification test is carried out on the composition according to the guiding principle of bacteriostatic efficacy detection method specified in appendix of 'two parts of Chinese pharmacopoeia 2010 edition'. The test results are shown in tables 6 to 7.
Table 6 results of composition test of example 1 and example 5
TABLE 7 examination results of compositions of comparative examples 1 to 3
According to the table 6 and the table 7, the combination of taurine and naphthylamine vitamin eye drops has synergistic effect on bacteriostasis.
In summary, the ophthalmic pharmaceutical compositions provided in embodiments 1 to 6 of the present invention, by using taurine and naphazoline hydrochloride, vitamin B12 and chlorpheniramine together, have synergistic effects, improve the therapeutic effect on conjunctivitis, and have good therapeutic effects on congestion, edema and the like caused by inflammation, and the combination can significantly reduce the side effects of the composition, reduce the irritation of the composition to the eyes, and improve the experience of the patients in medication.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (15)
1. Preparation of medicinal composition for eyeThe application of the medicine for the pressure rebound phenomenon is characterized in that every 1000ml of the composition comprises 0.05-0.15g of naphazoline hydrochloride, 3.2-5.8g of taurine, 0.1-0.3gpH regulator, 0.05-0.15g of osmotic pressure regulator, 0.01-0.05g of metal ion complexing agent, 0.2-0.5g of vitamin B12And 0.1-0.3g chlorpheniramine.
2. The use according to claim 1, wherein the composition comprises 0.08-0.1g naphazoline hydrochloride, 4-5g taurine, 0.15-0.2g pH regulator, 0.1-0.12g osmotic pressure regulator, 0.03-0.04g metal ion complexing agent, 0.3-0.4g vitamin B per 1000ml12And 0.15-0.25g of said chlorpheniramine.
3. Use according to claim 1 or 2, characterized in that the pH adjusting agent is an inorganic acid.
4. Use according to claim 3, wherein the pH adjusting agent is a monobasic acid.
5. Use according to claim 3, characterized in that the pH regulator is boric acid.
6. Use according to claim 1 or 2, wherein the osmolality adjusting agent is organic.
7. Use according to claim 6, wherein the osmolality adjusting agent is an alcohol.
8. Use according to claim 6, wherein the osmolality adjusting agent is a polyol.
9. Use according to claim 6, wherein the osmolality adjusting agent is glycerol.
10. Use according to claim 1 or 2, wherein the metal ion complexing agent is an aminopolycarboxylic acid metalloid complexing agent.
11. The use according to claim 10, wherein the metal ion complexing agent is disodium edetate.
12. Use according to claim 1 or 2, characterized in that it further comprises 0.01-0.03g of a preservative per 1000ml of the composition, said preservative being a cationic surfactant.
13. Use according to claim 12, characterized in that the preservative is benzalkonium bromide.
14. Use according to claim 1 or 2, characterized in that said composition is prepared by a process comprising the following steps: naphazoline hydrochloride, taurine, pH regulator, osmotic pressure regulator, metal ion complexing agent and vitamin B12And chlorpheniramine to form the composition.
15. The use according to claim 14, wherein the composition is prepared by heating water for injection to 60-80 ℃, mixing with an osmotic pressure regulator, a metal ion complexing agent and a pH regulator, and mixing with naphazoline hydrochloride, chlorpheniramine, vitamin B12 and taurine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811551020.2A CN109453151B (en) | 2018-12-18 | 2018-12-18 | Pharmaceutical composition for eyes, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811551020.2A CN109453151B (en) | 2018-12-18 | 2018-12-18 | Pharmaceutical composition for eyes, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109453151A CN109453151A (en) | 2019-03-12 |
| CN109453151B true CN109453151B (en) | 2021-03-26 |
Family
ID=65613695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811551020.2A Active CN109453151B (en) | 2018-12-18 | 2018-12-18 | Pharmaceutical composition for eyes, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109453151B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114099505B (en) * | 2021-12-07 | 2023-10-27 | 湖北远大天天明制药有限公司 | Ophthalmic composition, preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1839834A (en) * | 2006-01-26 | 2006-10-04 | 崔彬 | Eye medicine for preventing and treating asthenopia and allergy |
| CN101455636A (en) * | 2009-01-06 | 2009-06-17 | 河北科技大学 | Naphazoline hydrochloride, chlorphenamine maleate and vitamin B12 eye drops without bacteria inhibitor and preparation method thereof |
| CN102210856A (en) * | 2011-06-02 | 2011-10-12 | 陕西巨子生物技术有限公司 | Collagen eye drops and preparation method thereof |
-
2018
- 2018-12-18 CN CN201811551020.2A patent/CN109453151B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1839834A (en) * | 2006-01-26 | 2006-10-04 | 崔彬 | Eye medicine for preventing and treating asthenopia and allergy |
| CN101455636A (en) * | 2009-01-06 | 2009-06-17 | 河北科技大学 | Naphazoline hydrochloride, chlorphenamine maleate and vitamin B12 eye drops without bacteria inhibitor and preparation method thereof |
| CN102210856A (en) * | 2011-06-02 | 2011-10-12 | 陕西巨子生物技术有限公司 | Collagen eye drops and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109453151A (en) | 2019-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2877184B1 (en) | Compositions and treatment for eye diseases and disorders | |
| Shah et al. | A novel lidocaine hydrochloride ophthalmic gel for topical ocular anesthesia | |
| JP2022541854A (en) | Compositions and methods for treating presbyopia | |
| CN108125996A (en) | It is a kind of for visual fatigue, dry eyes eye-drops preparations | |
| CN109453151B (en) | Pharmaceutical composition for eyes, preparation method and application thereof | |
| CN103565734B (en) | Bendazac lysine eye drops as well as preparation method thereof | |
| CN105213418B (en) | A kind of preoperative compound eye drops and preparation method thereof of ophthalmology | |
| CN113786380A (en) | Pilocarpine nitrate ophthalmic gel and preparation method thereof | |
| CN108066282B (en) | A kind of Levofloxacin Eye drop and preparation method thereof | |
| CN109200016A (en) | A kind of Benzydalysine eye drop and preparation method thereof and purposes | |
| CN105168237A (en) | Compound gel moisturizing eye drops | |
| CN100362991C (en) | Medicine composition for ophthalmology department | |
| US20110268817A1 (en) | Compounds useful for the prevention or treatment of accomodative asthenopia | |
| CN102018656A (en) | Eye gel containing latanoprost used as effective component and preparation method thereof | |
| CN102512362B (en) | Formula and preparation method of compound ciprofloxacin eye drops | |
| RU2397776C2 (en) | Ophthalmologic composition | |
| CN105214092B (en) | RHuIL-1Ra and combinations thereof and medicinal usage | |
| TW202002980A (en) | Methods of use and pharmaceutical compositions of a selective SYK inhibitor | |
| CN103893742B (en) | Containing the application of the outer albumen 1 of vitellinae membrana in preparation treatment dry eye drug | |
| CN116270442A (en) | Ophthalmic preparation for correcting near vision | |
| Garrigue et al. | A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models | |
| CN115300502A (en) | Application of melatonin in preparing medicine for preventing and treating eye myopia, dosage form and preparation method thereof | |
| TWI632913B (en) | Compositions and treatment for eye diseases and disorders | |
| CN115957217A (en) | Eye preparation, preparation method and application | |
| US20060058345A1 (en) | Use of papaverine-like vasodilator and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |